[HTML][HTML] HLA-G/LILRBs: a cancer immunotherapy challenge
ED Carosella, S Gregori, D Tronik-Le Roux - Trends in Cancer, 2021 - cell.com
ED Carosella, S Gregori, D Tronik-Le Roux
Trends in Cancer, 2021•cell.comDespite some success, many patients do not benefit from immunotherapy. New strategies to
improve clinical efficacy include identification of novel immune-checkpoint (IC) targets or a
combination of immunotherapy with antiangiogenic treatments. Here, we propose the
therapeutic use of IC, HLA-G/LILRB, and explore its enhanced synergistic antitumor activity
when combined with antiangiogenic therapies.
improve clinical efficacy include identification of novel immune-checkpoint (IC) targets or a
combination of immunotherapy with antiangiogenic treatments. Here, we propose the
therapeutic use of IC, HLA-G/LILRB, and explore its enhanced synergistic antitumor activity
when combined with antiangiogenic therapies.
Despite some success, many patients do not benefit from immunotherapy. New strategies to improve clinical efficacy include identification of novel immune-checkpoint (IC) targets or a combination of immunotherapy with antiangiogenic treatments. Here, we propose the therapeutic use of IC, HLA-G/LILRB, and explore its enhanced synergistic antitumor activity when combined with antiangiogenic therapies.
cell.com